Riamilovir sodium hydrate
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330050

CAS#: 928659-17-0 (sodium hydrate)

Description: Riamilovir, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad-spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2.


Chemical Structure

img
Riamilovir sodium hydrate
CAS# 928659-17-0 (sodium hydrate)

Theoretical Analysis

MedKoo Cat#: 330050
Name: Riamilovir sodium hydrate
CAS#: 928659-17-0 (sodium hydrate)
Chemical Formula: C5H8N6Na2O5S
Exact Mass:
Molecular Weight: 310.1955
Elemental Analysis: C, 19.36; H, 2.60; N, 27.09; Na, 14.82; O, 25.79; S, 10.34

Price and Availability

Size Price Availability Quantity
50.0mg USD 350.0 2 Weeks
100.0mg USD 550.0 2 Weeks
200.0mg USD 950.0 2 Weeks
500.0mg USD 1950.0 2 Weeks
1.0g USD 2950.0 2 Weeks
2.0g USD 5150.0 2 Weeks
5.0g USD 8950.0 2 Weeks
Bulk inquiry

Related CAS #: 116061-59-7 (sodium)   123606-06-4 (free)   928659-17-0 (sodium hydrate)  

Synonym: Riamilovir sodium hydrate; Riamilovir; Triazavirin; TZV;

IUPAC/Chemical Name: 7-(Methylthio)-3-nitro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(6H)-one sodium sodium dihydrate

InChi Key: RPBLQPMOBSLKTG-UHFFFAOYSA-N

InChi Code: InChI=1S/C5H4N6O3S.2Na.2H2O/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5;;;;/h1H3,(H,6,8,9);;;2*1H2

SMILES Code: O=C1N(NC(SC)=N2)C2=NN=C1[N+]([O-])=O.[H]O[H].[H]O[H].[Na].[Na]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 310.1955 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message

Sent On: Thu Oct 15 14:14:09 2020

Search: Triazavirin

18 selected items

PubMed Results
Items 1-18 of 18 (Display the 18 citations in PubMed)

1: Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Wang W, Zhao M, Wu X, Zhang Y, Li L, Li K, Du Z, Mol BWJ, Yang B. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing). 2020 Sep 8. doi: 10.1016/j.eng.2020.08.011. Epub ahead of print. PMID: 32923016; PMCID: PMC7476906.

2: Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Zhao M, Zhang Y, Li K, Du Z, Yang B. The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol. Engineering (Beijing). 2020 Jul 3. doi: 10.1016/j.eng.2020.06.011. Epub ahead of print. PMID: 32837750; PMCID: PMC7332434.

3: Shahab S, Sheikhi M. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Curr Mol Med. 2020 May 20. doi: 10.2174/1566524020666200521075848. Epub ahead of print. PMID: 32436829.

4: Zabrodskaya YA, Shvetsov AV, Tsvetkov VB, Egorov VV. A double-edged sword: supramolecular complexes of triazavirine display multicenter binding effects which influence aggregate formation. J Biomol Struct Dyn. 2019 Aug;37(12):3041-3047. doi: 10.1080/07391102.2018.1507837. Epub 2018 Nov 15. PMID: 30073907.

5: Shvetsov AV, Zabrodskaya YA, Nekrasov PA, Egorov VV. Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. J Biomol Struct Dyn. 2018 Aug;36(10):2694-2698. doi: 10.1080/07391102.2017.1367329. Epub 2017 Sep 12. PMID: 28828928.

6: Kozhikhova KV, Ivantsova MN, Tokareva MI, Shulepov ID, Tretiyakov AV, Shaidarov LV, Rusinov VL, Mironov MA. Preparation of chitosan-coated liposomes as a novel carrier system for the antiviral drug Triazavirin. Pharm Dev Technol. 2018 Apr;23(4):334-342. doi: 10.1080/10837450.2016.1242624. Epub 2016 Oct 25. PMID: 27681534.

7: Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV. [Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]. Antibiot Khimioter. 2015;60(7-8):11-3. Russian. PMID: 26863736.

8: Loginova SY, Borisevich SV, Rusinov VL, Ulomsky UN, Charushin VN, Chupakhin N, Sorokin PV. [Investigation of Prophylactic Efficacy of Triazavirin Against Experimental Forest- Spring Encephalitis on Albino Mice]. Antibiot Khimioter. 2015;60(5-6):8-11. Russian. PMID: 26852489.

9: Blazhennikova IV, Kurliakova AF, Bykov VN, Geĭbo DS, Nikiforov AS, Stepanov AV, Charushin VN, Chupakhin ON, Kotovskaia SK, Rusinov VL. [Experimental comparative pharmacokinetics of levofloxacin, triazavirin, and related conjugate]. Eksp Klin Farmakol. 2015;78(2):34-8. Russian. PMID: 25898546.

10: Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Investigation of Triazavirin antiviral activity against tick- borne encephalitis pathogen in cell culture]. Antibiot Khimioter. 2014;59(1-2):3-5. Russian. PMID: 25051708.

11: Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, Charushin VN, Chupakhin ON. [A new antiviral drug Triazavirin: results of phase II clinical trial]. Vopr Virusol. 2012 Nov-Dec;57(6):9-12. Russian. PMID: 23477247.

12: Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Toxicity of triazavirin, a novel Russian antiinfluenza chemotherapeutic]. Antibiot Khimioter. 2012;57(11-12):8-10. Russian. PMID: 23700930.

13: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. Antibiot Khimioter. 2011;56(1-2):10-2. Russian. PMID: 21780665.

14: Smirnova TD, Danilenko DM, Eropkin MIu, Deeva EG, Kiselev OI. [Influence of rimantadine, ribavirine and triazavirine on influenza A virus replication in human monolayer and lymphoblastoid cell lines]. Antibiot Khimioter. 2011;56(11-12):11-6. Russian. PMID: 22856151.

15: Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, Deeva E, Yanvarev D, Ivanov A, Smirnova O, Kochetkov S, Chupakhin O, Kukhanova M. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob Agents Chemother. 2010 May;54(5):2017-22. doi: 10.1128/AAC.01186-09. Epub 2010 Mar 1. PMID: 20194696; PMCID: PMC2863629.

16: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiot Khimioter. 2010;55(9-10):25-8. Russian. PMID: 21400750.

17: Lukovnikova LV, Sidorin GI, D'iakova LI, Skhodkina NI, Bitti MA, Cherkashchenko OS. [Basing approximate safe level of exposure to Triazavirin in air of workplace]. Med Tr Prom Ekol. 2009;(4):44-7. Russian. PMID: 19514171.

18: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN. [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. Antibiot Khimioter. 2007;52(11-12):18-20. Russian. PMID: 19275052.